These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36473984)

  • 1. Modeling Dual Drug Delivery from Eluting Stents: The Influence of Non-Linear Binding Competition and Non-Uniform Drug Loading.
    Salvi S; Jain A; Pontrelli G; McGinty S
    Pharm Res; 2023 Jan; 40(1):215-230. PubMed ID: 36473984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical modelling of endovascular drug delivery: Balloons versus stents.
    Escuer J; Schmidt AF; Peña E; Martínez MA; McGinty S
    Int J Pharm; 2022 May; 620():121742. PubMed ID: 35427751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual drug-eluting stents coated with multilayers of hydrophobic heparin and sirolimus.
    Su LC; Chen YH; Chen MC
    ACS Appl Mater Interfaces; 2013 Dec; 5(24):12944-53. PubMed ID: 24294944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of sirolimus-eluting stents compared with paclitaxel-eluting stents in an unselected population with coronary artery disease: 24-month outcomes of patients in a prospective non-randomized registry in Southern Turkey.
    Ciçek D; Pekdemir H; Kalay N; Binici S; Altay H; Müderrisoğlu H
    Int J Med Sci; 2010 Jun; 7(4):191-6. PubMed ID: 20596361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcome of Turkish patients treated with Zotarolimus versus Paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern Turkey.
    Ciçek D; Pekdemir H; Haberal C; Kalay N; Binici S; Altay H; Müderrisoğlu H
    Int J Med Sci; 2011 Jan; 8(1):68-73. PubMed ID: 21234271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary Stents in Diabetic Patients: State of the Knowledge.
    Codner P; Gurm HS; Motivala A
    Curr Cardiol Rep; 2017 Apr; 19(4):28. PubMed ID: 28315123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
    Iakovou I; Schmidt T; Bonizzoni E; Ge L; Sangiorgi GM; Stankovic G; Airoldi F; Chieffo A; Montorfano M; Carlino M; Michev I; Corvaja N; Briguori C; Gerckens U; Grube E; Colombo A
    JAMA; 2005 May; 293(17):2126-30. PubMed ID: 15870416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.